Evidence map›Paper›PMID 35861464›Full record

ArticleRespirology (Carlton, Vic.)2022

Treatable traits in the NOVELTY study.

Alvar Agustí, Eleni Rapsomaniki, Richard Beasley, Rod Hughes, Hana Müllerová, Alberto Papi, Ian D Pavord, Maarten van den Berge, Rosa Faner, NOVELTY Study Investigators

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in Respirology (Carlton, Vic.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02760329 (A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.), which is not on this map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02760329 completednot on this map

A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.

TypeobservationalSponsorAstraZenecaRan2016 to 2023Enrolled12,255ConditionsAsthma, COPD, Chronic Obstructive Pulmonary DiseaseArmsBlood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO)
3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Trial
  2. Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD?International journal of chronic obstructive pulmonary disease · 2023
    Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. The value of treatable traits across the spectrum of adult asthma severity.Chinese medical journal pulmonary and critical care medicine · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Alvar AgustíCàtedra Salut Respiratoria, Universitat Barcelona, Barcelona, Spain.ORCID 0000-0003-3271-3788
Eleni RapsomanikiBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Richard BeasleyMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID 0000-0003-0337-406X
Rod HughesExternal Scientific Engagement, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Hana MüllerováRespiratory & Immunology, Medical and Payer Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Alberto PapiDepartment of Respiratory Medicine, Medical School, University of Ferrara, Ferrara, Italy.ORCID 0000-0002-6924-4500
Ian D PavordOxford Respiratory NIHR BRC and Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-4288-5973
Maarten van den BergeDepartment of Pulmonary Diseases, Medical Center Groningen, Groningen, The Netherlands.
Rosa FanerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID 0000-0002-8159-0115
NOVELTY Study Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveAsthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of 'asthma', 'COPD' or 'asthma + COPD'.

methodsThe authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with 'asthma' (n = 5932, 52.8%), 'COPD' (n = 3898, 34.7%) or both ('asthma + COPD'; n = 1396, 12.4%).

resultsThe results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with 'asthma', 'COPD' and 'asthma + COPD', respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity.

conclusionThese results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.

Indexed as

AsthmaPulmonary Disease, Chronic ObstructiveHumansLongitudinal StudiesPhenotypePrevalenceairwaysallergyasthmabronchitischronic obstructive pulmonary diseaseCOPDemphysemasmoking

Identifiers

PMID35861464
PMCPMC9795904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.